WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 314216
CAS#: 22316-47-8
Description: Clobazam is a benzodiazepine derivative. It has been marketed as an anxiolytic since 1975 and an anticonvulsant since 1984. Clobazam is discontinued.
MedKoo Cat#: 314216
Name: Clobazam
CAS#: 22316-47-8
Chemical Formula: C16H13ClN2O2
Exact Mass: 300.06656
Molecular Weight: 300.74
Elemental Analysis: C, 63.90; H, 4.36; Cl, 11.79; N, 9.31; O, 10.64
Clobazam is not available (This is a controlled substance: Controlled Substance Sch IV)
Synonym: Frisium; Urbanol; Onfi; H-4723; HR 376; HSDB 8343; LM 2717; LM-2717; Noiafren; NSC 336279; RU-4723; Urbadan; Urbanil; Urbanyl.
IUPAC/Chemical Name: 7-Chloro-1-methyl-5-phenyl-1,5-benzodiazepine-2,4(3H)-dione
InChi Key: CXOXHMZGEKVPMT-UHFFFAOYSA-N
InChi Code: InChI=1S/C16H13ClN2O2/c1-18-13-8-7-11(17)9-14(13)19(16(21)10-15(18)20)12-5-3-2-4-6-12/h2-9H,10H2,1H3
SMILES Code: O=C(C1)N(C)C2=CC=C(Cl)C=C2N(C3=CC=CC=C3)C1=O
The following data is based on the product molecular weight 300.74 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
1: Purcarin G, Ng YT. Experience in the use of clobazam in the treatment of Lennox-Gastaut syndrome. Ther Adv Neurol Disord. 2014 May;7(3):169-176. Review. PubMed PMID: 24790647; PubMed Central PMCID: PMC3994921.
2: Cramer JA, Sapin C, François C. Indirect comparison of clobazam and other therapies for Lennox-Gastaut syndrome. Acta Neurol Scand. 2013 Aug;128(2):91-9. doi: 10.1111/ane.12086. Epub 2013 Feb 15. Review. PubMed PMID: 23410109.
3: de Leon J, Spina E, Diaz FJ. Clobazam therapeutic drug monitoring: a comprehensive review of the literature with proposals to improve future studies. Ther Drug Monit. 2013 Feb;35(1):30-47. doi: 10.1097/FTD.0b013e31827ada88. Review. PubMed PMID: 23318278; PubMed Central PMCID: PMC3546316.
4: Owen RT. The use of clobazam as an adjunctive treatment for Lennox-Gastaut syndrome. Drugs Today (Barc). 2012 Nov;48(11):697-703. doi: 10.1358/dot.2012.48.11.1879453. Review. PubMed PMID: 23170305.
5: Wheless JW, Phelps SJ. Clobazam: a newly approved but well-established drug for the treatment of intractable epilepsy syndromes. J Child Neurol. 2013 Feb;28(2):219-29. doi: 10.1177/0883073812463609. Epub 2012 Oct 30. Review. PubMed PMID: 23112237.
6: Yang LP, Scott LJ. Clobazam : in patients with Lennox-Gastaut syndrome. CNS Drugs. 2012 Nov;26(11):983-91. doi: 10.1007/s40263-012-0007-0. Review. PubMed PMID: 23034582.
7: Seif-Eddeine H, Ng YT. Clobazam for patients with Lennox-Gastaut syndrome and epilepsy. Expert Rev Neurother. 2012 Apr;12(4):385-93. doi: 10.1586/ern.12.14. Review. PubMed PMID: 22449211.